Xuebijing injection for sepsis-associated acute kidney injury treatment: a systematic review and meta-analysis

doi:10.5246/jcps.2025.12.085

Abstract

Abstract:

Sepsis-associated acute kidney injury (SA-AKI) represents a leading contributor to the elevated mortality observed in sepsis patients. In the present study, we conducted a comprehensive meta-analysis to assess the clinical effectiveness of continuous renal replacement therapy (CRRT) in combination with Xuebijing injection for the treatment of SA-AKI. A systematic search was performed across major databases, including CNKI, VIP, Sinomed, WanFang, PubMed, and the Cochrane Library, covering publications up to January 2025. Quality assessment and statistical analyses were carried out using RevMan 5.4. The pooled results demonstrated that the adjunctive use of Xuebijing injection with CRRT, as compared to CRRT alone, yielded significantly better outcomes. Specifically, this combined therapy was associated with enhanced recovery of renal function, more effective clearance of inflammatory mediators, improved immune modulation, better regulation of coagulation parameters, and a marked reduction in mortality among SA-AKI patients.

Key words: Xuebijing injection, CRRT, Sepsis, Acute kidney injury, Meta-analysis

Supporting:

Yajing Li, Tengfei Chen, Changhong Yan, Yawen Bai, Haoyang Yan, Qingquan Liu. Xuebijing injection for sepsis-associated acute kidney injury treatment: a systematic review and meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(12): 1126-1143.

Figures/Tables 18

Table 1. General information on the included literature.

References 38

[1]	Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; Hotchkiss, R.S.; Levy, M.M.; Marshall, J.C.; Martin, G.S.; Opal, S.M.; Rubenfeld, G.D.; van der Poll, T.; Vincent, J.L.; Angus, D.C. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016, 315, 801–810.
[2]	Qiao, J.; Cui, L.Y. Multi-omics techniques make it possible to analyze sepsis-associated acute kidney injury comprehensively. Front. Immunol. 2022, 13, 905601.
[3]	Poston, J.T.; Koyner, J.L. Sepsis associated acute kidney injury. BMJ. 2019, 364, k4891.
[4]	Barbar, S.D.; Clere-Jehl, R.; Bourredjem, A.; Hernu, R.; Montini, F.; Bruyère, R.; Lebert, C.; Bohé, J.; Badie, J.; Eraldi, J.P.; Rigaud, J.P.; Levy, B.; Siami, S.; Louis, G.; Bouadma, L.; Constantin, J.M.; Mercier, E.; Klouche, K.; du Cheyron, D.; Piton, G.; Annane, D.; Jaber, S.; van der Linden, T.; Blasco, G.; Mira, J.P.; Schwebel, C.; Chimot, L.; Guiot, P.; Nay, M.A.; Meziani, F.; Helms, J.; Roger, C.; Louart, B.; Trusson, R.; Dargent, A.; Binquet, C.; Quenot, J.P.; IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N. Engl. J. Med. 2018, 379, 1431–1442.
[5]	Zarbock, A.; Nadim, M.K.; Pickkers, P.; Gomez, H.; Bell, S.; Joannidis, M.; Kashani, K.; Koyner, J.L.; Pannu, N.; Meersch, M.; Reis, T.; Rimmelé, T.; Bagshaw, S.M.; Bellomo, R.; Cantaluppi, V.; Deep, A.; De Rosa, S.; Perez-Fernandez, X.; Husain-Syed, F.; Kane-Gill, S.L.; Kelly, Y.; Mehta, R.L.; Murray, P.T.; Ostermann, M.; Prowle, J.; Ricci, Z.; See, E.J.; Schneider, A.; Soranno, D.E.; Tolwani, A.; Villa, G.; Ronco, C.; Forni, L.G. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat. Rev. Nephrol. 2023, 19, 401–417.
[6]	Chang, Y.M.; Chou, Y.T.; Kan, W.C.; Shiao, C.C. Sepsis and acute kidney injury: a review focusing on the bidirectional interplay. Int. J. Mol. Sci. 2022, 23, 9159.
[7]	Li, C.Y.; Wang, P.; Li, M.; Zheng, R.; Chen, S.Q.; Liu, S.; Feng, Z.Q.; Yao, Y.M.; Shang, H.C. The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms. J. Ethnopharmacol. 2021, 265, 113301.
[8]	Wang, H.; Kang, X.; Shi, Y.; Bai, Z.H.; Lv, J.H.; Sun, J.L.; Pei, H.H. SOFA score is superior to APACHE-II score in predicting the prognosis of critically ill patients with acute kidney injury undergoing continuous renal replacement therapy. Ren. Fail. 2020, 42, 638–645.
[9]	Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 2012, 120, c179–c184.
[10]	Liu, S.Q.; Yao, C.; Xie, J.F.; Liu, H.; Wang, H.L.; Lin, Z.F.; Qin, B.Y.; Wang, D.F.; Lu, W.H.; Ma, X.C.; Liu, Y.; Liu, L.; Zhang, C.; Xu, L.; Zheng, R.Q.; Zhou, F.H.; Liu, Z.M.; Zhang, G.Q.; Zhou, L.X.; Liu, J.; Fei, A.H.; Zhang, G.X.; Zhu, Y.M.; Qian, K.J.; Wang, R.L.; Liang, Y.F.; Duan, M.L.; Wu, D.W.; Sun, R.Q.; Wang, Y.; Zhang, X.J.; Cao, Q.; Yang, M.S.; Jin, M.G.; Song, Y.; Huang, L.; Zhou, F.C.; Chen, D.C.; Liang, Q.; Qian, C.Y.; Tang, Z.Z.; Zhang, Z.; Feng, Q.M.; Peng, Z.Y.; Sun, R.H.; Song, Z.J.; Sun, Y.B.; Chai, Y.F.; Zhou, L.H.; Cheng, C.; Li, L.; Yan, X.Y.; Zhang, J.H.; Huang, Y.Z.; Guo, F.M.; Li, C.; Yang, Y.; Shang, H.C.; Qiu, H.B.; Investigators, E.S. Effect of an herbal-based injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial. JAMA Inter. Med. 2023, 183, 647–655.
[11]	Yu, Z.; Wu, G. Effect of CRRT therapy combined with Xuebijing injection on APACHEII score and quality of life of patients with sepsis complicated by infectious acute kidney injury. J. Med. Forum. 2018, 39, 134–136.
[12]	Sun, J.; Zhang, X.K.; Fu, S.Z.; Dong, Y.; Zhao, Q.; Guan, B.X. Effects of continuous renal replacement therapy combined with Xuebijing on inflammatory response level, immune state and disease severity in sepsis patients. Guangdong Med. J. 2015, 36, 387–391.
[13]	Zhen, H.X. Analysis of the therapeutic effect of high-dose Xuebijing injection combined with continuous renal replacement therapy on patients with sepsis complicated by acute kidney injury. J. Med. Theory Pract. 2019, 22, 3646–3647.
[14]	Zhao, T. Efficacy analysis of high-dose Xuebijing injection combined with sequential blood purification in the treatment of sepsis complicated by acute kidney injury. Mod. Diagn. Treat. 2020, 13, 2078–2080.
[15]	Luo, C.J. Analysis of the role of Xuebijing combined with continuous renal replacement therapy in patients with sepsis complicated by acute kidney injury. Chin. Sci. Tech. J. Database Med. Health. 2021, 7, 45–46.
[16]	Jiang, Q.D.; Zhang, X.M.; Wu, C.X. Effects of continuous renal replacement therapy combined with different doses of Xuebijing injection on sepsis patients with acute kidney injury. China Pharm. 2017, 28, 1087–1091.
[17]	Xie, L.P.; Wang, C.Z. Effects of continuous renal replacement therapy combined with Xuebijing on T lymphocyte subsets in patients with sepsis complicated by acute kidney injury. Clin. Med. 2017, 12, 90–91.
[18]	Peng,Y.; Liang, Z.X.; Luo, L.; Hu, S. Effects of continuous renal replacement therapy combined with Xuebijing on immune function of patients with sepsis complicated by infectious acute kidney injury. J. Prev. Med. Chin. PLA. 2016, 34, 309.
[19]	Zheng, C.M.; Wang, Z.J.; Dou, H.H. Effect of Xuebijing injection on serum miR210 in elderly patients with acute renal injury induced by sepsis and its clinical significance. Chin. Foreign Med. Res. 2022, 20, 13–16.
[20]	Yu, H.C. Effects of Xuebijing combined with CRRT on urinary HGMB1, L-FABP and renal function in patients with sepsis complicated by acute kidney injury. Contemp. Med. 2021, 33, 119–120.
[21]	Zhou, B.; Chen, Y.L.; Huang, X. Effects of Xuebijing combined with CRRT on coagulation and renal function in patients with sepsis complicated by acute kidney injury. Clin. Med. Eng. 2021, 4, 465–466.
[22]	Dai, J.J.; Xue, J.; Wang, Z. Efficacy observation of Xuebijing combined with continuous blood purification in the treatment of patients with sepsis and acute kidney injury. Med. Health. 2022, 1, 29–31.
[23]	Liu, Y.B.; Liang, H.B.; Zeng, M.H.; Chen, J.; Huang, Y.H. Application effect of Xuebijing combined with continuous renal replacement therapy on sepsis patients complicated with acute kidney injury. Guangxi Med. J. 2020, 42, 1927–1930.
[24]	Zhao, L. Application effect of Xuebijing combined with continuous renal replacement therapy in patients with sepsis complicated by acute kidney injury. Med. J. Chin. People’s Health. 2020, 32, 18–20.
[25]	Huang, Y.; Liu, Y.J.; Wang, Z.L.; Quan. C.; Zhang, Q.Q.; Zhang, H.; Miao, C.W. Effects of Xuebijing injection on T lymphocyte subsets in patients with sepsis complicated by acute kidney injury. North. Pharmaceutical. J. 2021, 3, 475–478.
[26]	Huang, H. Efficacy observation of Xuebijing injection combined with CRRT blood purification in the treatment of patients with sepsis complicated by acute kidney injury. Electron. J. Clin. Med. Literat. 2019, 84, 60–61.
[27]	Song, Y.N.; Ren, C.H.; Li, Y.H.; Wang, W.L. Effect of Xuebijing injection combined with CRRT in the treatment of sepsis complicated with AKI and its influence on NGAL and TIMP-1. Shenzhen J. Integr. Tradit. Chin. West. Med. 2022, 32, 25–28.
[28]	Zhang, M.; Fang, Y.; Zhao, Z. Efficacy of Xuebijing injection combined with continuous renal replacement therapy in the treatment of patients with sepsis complicated by acute kidney injury. J. Chin. Phys. 2019, 8, 1239–1240.
[29]	Li, J.P.; Wu, L.J.; Wang, X.H. Clinical study on Xuebijing injection combined with bedside CRRT in the treatment of patients with sepsis complicated by acute kidney injury. J. Med. Forum. 2019, 7, 142–143.
[30]	Lin, C.Q.; Zhai, X.L.; Zhang, L.F.; Chen, S. Effect of Xuebijing Injection on inflammatory factors, circulatory and respiratory function in patients with acute kidney injury due to sepsis. Chin. Arch. Tradit. Chin. Med. 2022, 40, 55–58.
[31]	Qiu, W.H.; An, S.; Wang, T.J.; Li, J.X.; Yu, B.M.; Zeng, Z.H.; Chen, Z.Q.; Lin, B.; Lin, X.Z.; Gao, Y.G. Melatonin suppresses ferroptosis via activation of the Nrf2/HO-1 signaling pathway in the mouse model of sepsis-induced acute kidney injury. Int. Immunopharmacol. 2022, 112, 109162.
[32]	Gierlikowska, B.; Stachura, A.; Gierlikowski, W.; Demkow, U. The impact of cytokines on neutrophils’ phagocytosis and NET formation during sepsis-a review. Int. J. Mol. Sci. 2022, 23, 5076.
[33]	Bakhshiani, Z.; Fouladi, S.; Mohammadzadeh, S.; Eskandari, N. Correlation of sPD1 with procalcitonin and C-reactive protein levels in patients with sepsis. Cell J. 2021, 1, 14–20.
[34]	Padovani, C.M.; Yin, K. Immunosuppression in sepsis: Biomarkers and specialized pro-resolving mediator. Biomedicines. 2024, 12, 175.
[35]	Park, J.T.; Lee, H.; Kee, Y.K.; Park, S.; Oh, H.J.; Han, S.H.; Joo, K.W.; Lim, C.S.; Kim, Y.S.; Kang, S.W.; Yoo, T.H.; Kim, D.K.; Jo, H.A.; Han, M.; Lee, S.; Kim, E.Y.; Yang, J.S.; Lee, M.J.; Kwon, Y.E.; Park, K.S.; Kee, Y.K.; Han, S.G.; Han, I.M.; Yoon, C.Y.; Ryu, G.W.; Jhee, J.H.; Kim, H.W.; Park, S.; Jung, S.Y.; Kim, E.K.; Kim, M.H.; Kim, Y.J.; Jang, Y.H.; Kim, M.R.; Song, K.J.; Kim, M.A.; Hyun, J.Y.; Choi, B.N. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial. Am. J. Kidney Dis. 2016, 68, 599–608.
[36]	Cho, A.Y.; Yoon, H.J.; Lee, K.Y.; Sun, I.O. Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy. Ren. Fail. 2018, 40, 403–409.
[37]	Zhao, J; Feng, L.X.; Shi, J.X.; Fan, F.J. Guiding significance of immune factors and T lymphocyte subsets in immunomodulatory therapy for sepsis. Chin. J. Immunol. 2024, 40, 2614–2622.
[38]	Ying, L.J.; Cao, X.J.; Chen, M.X. Expressions of T lymphocyte subsets in peripheral blood of infants and clinical significance. Chin. J. Nosocomiol. 2022, 32, 3312–3316.